The first half of 2020 saw the advent of coronavirus disease 2019 (COVID-19) as a pandemic, which had an immediate and significant impact on cancer care. The COVID-19 pandemic has had a wide-ranging detrimental effect on cancer care, with variable degrees of severity in different places throughout the world. Patients with cancer are a vulnerable population, and they are exposed to a variety of problems during pandemics, including infection susceptibility and disruption of their cancer or regular medical care. Potential cardiovascular complications in cancer patients who have also been infected with SARS-CoV-2 are one of the most pressing concerns for clinicians. The renin-angiotensin-aldosterone system (RAAS) is another area of concern in COVID-19 positive cancer patients.
Title :
Pietro Salvatori, Private Practice, Italy
Title :
Jianhua Luo, University of Pittsburgh, United States
Title :
Marika Crohns, Sanofi, Germany
Title : RNA binding proteins in the pathogenesis of pediatric cancer
Atif A Ahmed, University of Washington-Seattle Children’s Hospital, United States
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title : The future of pharmacogenetic polymorphism, pharmacogenomics and pharmamicrobiome in cancer treatment
Bene Ekine-Afolabi, University of East London, United Kingdom